Korro Bio(KRRO) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024, and provided an update on its recent progress and anticipated milestones. • Appointed Dr. Kemi Olug ...